Press release content from Business Wire. The AP news staff was not involved in its creation.

Therapeutic Solutions International Identifies Novel Cellular Marker Associated with Therapeutic Response to JadiCell Stem Cell Treatment

PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.
January 9, 2023 GMT

ELK CITY, Idaho--(BUSINESS WIRE)--Jan 9, 2023--

Therapeutic Solutions International (TSOI) announced today identification and patent filing of a previously unexpected discovery that responsiveness to JadiCell stem cell therapy appears to correlate with alternations of a specific type of B cell producing the cytokine interleukin-10 and possessing unique surface markers.

These types of B cells, which are related to a cell type previously associated with pregnancy, appear to play a role in controlling pathological immunity, as well as producing factors that may be involved in healing injured tissues.

Therapeutic Solutions International has a Phase III clinical trial ongoing for COVID-19 acute respiratory distress syndrome (ARDS) and has been granted IND numbers for use of JadiCells in Chronic Obstructive Pulmonary Disease (COPD) and Chronic Traumatic Encephalopathy. Additionally, the Company has active, ongoing, collaborations with physicians to provide the cells under Emergency IND and Right to Try.


“As a Principal Investigator for these clinical trials, it is difficult to overstate how important it is to possess a marker that appears to predict responsiveness to our stem cell therapy,” said Dr. James Veltmeyer, Chief Medical Officer of the Company, and co-inventor of the patent. “From preliminary data in patients, and also in our laboratory research, it appears that this marker may be predictive for efficacy of other stem cells besides JadiCells.”

“The field of biotechnology in general is aiming for the Holy Grail called ‘Personalized Medicine’. The findings disclosed today, we feel, bring Personalized Medicine to the area of Regenerative Medicine and Regenerative Psychiatry,” said Timothy Dixon, President, and CEO of the Company and co-inventor. “Significant sums of money are routinely spent on clinical trials that do not provide efficacy data. Many believe that this occurs simply because we are not choosing the right patients. It is reasonable to believe that if today’s results are reproducible on a larger scale, we will possess a new tool to advance the field of stem cell sciences.”

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company’s corporate website is


View source version on

CONTACT: Timothy G. Dixon



SOURCE: Therapeutic Solutions International, Inc.

Copyright Business Wire 2023.

PUB: 01/09/2023 09:00 AM/DISC: 01/09/2023 09:03 AM